Currency in USD Email Alerts AIM ImmunoTech 2019-09-03T14:37:10-04:00 Welcome to the communications center and thank you for your interest!
After the World Health Organization chief said a coronavirus vaccine could be ready in 18 months, AIM ImmunoTech Inc. CEO Thomas Equels says Ampligen might be helpful in the meantime.
AIM's flagship products include the Argentina-approved drug rintatolimod (trade names Ampligen ® or Rintamod ® ) and the FDA-approved drug Alferon N Injection ® .
Welcome to the communications center and thank you for your interest!To add or remove yourself from our email list, enter your email address below.It is our goal to provide you with the highest quality of information. Twitter. By completing the following form, you can request to receive corporate communication email, request investor mailings, attend online corporate events and provide your valuable feedback directly to management at any time.Thank you and we look forward to serving your information needs. Twitter. Over the last 52 weeks, AIM is down -61.04% while the S&P 500 is down -0.83%. AIM Immunotech Is Playing a Significant Role in This Project AIM’s participation and collaboration in this study are very vital in making this project a success.
Currently at 0.32 is the 14-day ATR for AIM ImmunoTech Inc. (AIM). Pinterest.
AIM's flagship products include the Argentina-approved drug rintatolimod (trade names Ampligen ® or Rintamod ® ) and the FDA-approved drug Alferon N Injection ® . To add or remove yourself from our email list, enter your email address below.
Twitter. The company, currently valued at $99.34 Million, closed the recent trade at $3.02 per share which meant it gained $0.03 on the day or 1.04% during that session.
Pinterest.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers. AIM ImmunoTech Inc. (NYSE:AIM) has a beta value of -0.82 and has seen 3,886,723 shares traded in the last trading session. The AIM ImmunoTech Inc. (AIM) shares are trading at lower $2.77 and the avg recommendation for the stock is Moderate Buy. First, the company has made a name in the development of therapeutics for multiple types of cancers. WhatsApp.
The company, currently valued at $95.26 Million, closed the last trade at $2.92 per share which meant it gained $0.15 on the day or 5.42% during that session. LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.Jeff Bishop Went From Rags To Riches And Made Millions Trading Stocks And Options From Home. Twitter. PRODUCT NAME.
He's Now Helping Others By Sharing His Top Picks.LOS ANGELES, CA / ACCESSWIRE / August 3, 2020 / The SNN Network Virtual Conference will take place on August 3rd \\- 6th, 2020, where 49 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.Discover new investment ideas by accessing unbiased, in-depth investment researchNYSE American - Nasdaq Real Time Price. WhatsApp.
Traders and investors may also choose to study the ATR or Average True Range when concentrating on technical inventory assessment. Products AIM ImmunoTech 2019-04-18T19:19:07-04:00.
Pinterest. WhatsApp.
AIM ImmunoTech Inc. (NYSE:AIM) has a beta value of -0.9 and has seen 1,156,172 shares traded in the recent trading session.
Find the latest AIM ImmunoTech Inc. (AIM) stock quote, history, news and other vital information to help you with your stock trading and investing.
Twitter. AIM ImmunoTech Inc. (AMEX:AIM) went up by 5.42% from its latest closing price when compared to the 1-year high value of $7.11 and move down -143.49%, while AIM stocks collected -4.89% of loss with the last five trading sessions.
WhatsApp. To add more color to this target, the company’s high over the last year is $7.11 and the low is $0.38. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers. Pinterest. Secondly, it … AIM ImmunoTech Inc. (AMEX:AIM) went up by 2.68% from its latest closing price when compared to the 1-year high value of $7.11 and move down -131.6%, while AIM stocks collected 8.48% of gains with the last five trading sessions. AIM ImmunoTech Inc. (AIM) shares reached a high of $3.16 and dropped to a low of $2.90 until finishing in the latest session at $3.13.